AstraZeneca (NASDAQ:AZN) announced Tuesday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA) ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments ...

Among patients with non–muscle-invasive bladder cancer, neoadjuvant mitomycin demonstrated ... Patients were randomly assigned to receive either neoadjuvant mitomycin C or no neoadjuvant therapy ...

EMA committee recommends approval of AstraZeneca’s Imfinzi to treat adult patients with resectable muscle-invasive bladder cancer: Cambridge, UK Tuesday, May 27, 2025, 15:00 Hrs ...

So we spoke about adjuvant therapy in bladder cancer. So let's talk about neoadjuvant therapy. Neoadjuvant therapy, arguably the standard of care. Cisplatin-based chemotherapy has shown a survival ...

Bladder cancer ... surgery or radiation left behind. Neoadjuvant chemotherapy shrinks the tumor to make it easier to treat. Why would I need adjuvant therapy if I don't have signs of cancer ...

A phase 2/3 multicenter trial evaluating safety and efficacy of a new mucoadhesive gemcitabine suspension for ablation of upper tract urothelial carcinoma. ABLE-22: Safety and efficacy evaluation of ...

(Alliance News) - AstraZeneca PLC on Tuesday said its Imfinzi, or durvalumab, therapy has been recommended for approval in the EU for the treatment of muscle-invasive bladder cancer.

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

For decades, the only neoadjuvant therapy proved beneficial in muscle-invasive bladder cancer was a combination of chemotherapy drugs, including cisplatin. This truly represented the standard ...